MedTrace Logo

A Study of Participants With Chronic Kidney Disease Previously Treated With REACT

NCT05694169 · Status: TERMINATED · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 1

Last updated 2025-02-28

No results posted yet for this study

Summary

The purpose of this study is to evaluate the safety of supplemental REACT injections in participants with chronic kidney disease (CKD) who have previously received REACT treatment.

Conditions

  • Diabetic Kidney Disease
  • CAKUT
  • Chronic Kidney Diseases

Interventions

BIOLOGICAL

Renal Autologous Cell Therapy (REACT)

Autologous selected renal cells (SRC)

Sponsors & Collaborators

  • Prokidney

    lead INDUSTRY

Principal Investigators

  • Study Director · Prokidney

Study Design

Allocation
NA
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
30 Years
Max Age
80 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2023-07-11
Primary Completion
2024-03-19
Completion
2024-05-13
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT05694169 on ClinicalTrials.gov